(02.23.21) – Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
(02.02.21) – Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
(01.12.21) – Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
(01.07.21) – Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
(11.12.20) – Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
